Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Gecacitinib Plus Luspatercept in Patients With Myelofibrosis and Anemia

9. november 2026 oppdatert av: Bing Han, Peking Union Medical College Hospital

Gecacitinib Combined With Luspatercept in Patients With Myelofibrosis and Anemia: A Single-center, Prospective, Single-arm Study

This single-center, prospective, single-arm study aims to evaluate the efficacy and safety of gecacitinib combined with luspatercept in patients with myelofibrosis and anemia who have not previously received a Janus kinase inhibitor. Participants will receive oral gecacitinib and subcutaneous luspatercept.

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

31

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Age 18 years or older.
  2. Confirmed primary myelofibrosis according to the 2016 World Health Organization diagnostic criteria, or post-polycythemia vera or post-essential thrombocythemia myelofibrosis according to the International Working Group for Myeloproliferative Neoplasms Research and Treatment diagnostic criteria.
  3. Intermediate-2 or high-risk disease according to the Dynamic International Prognostic Scoring System (DIPSS) or DIPSS-plus, or intermediate-1-risk disease with hepatosplenomegaly that is unresponsive to existing treatment and requires treatment.
  4. No previous treatment with a Janus kinase inhibitor.
  5. Discontinuation of other myelofibrosis treatments, such as interferon or hydroxyurea, immunosuppressants, corticosteroids, and growth factors such as erythropoietin, for at least 2 weeks or 6 half-lives before study treatment.
  6. Splenomegaly, with the spleen palpable 5 cm below the left costal margin.
  7. Hemoglobin below 100 g/L, with or without red blood cell transfusion dependence.
  8. Platelet count of at least 75 × 10^9/L.
  9. Absolute neutrophil count of at least 1.0 × 10^9/L.
  10. Peripheral blood blasts of 10% or less.
  11. Eastern Cooperative Oncology Group performance status of 0-2 and a life expectancy of more than 6 months.
  12. Ability to independently provide written informed consent.

Exclusion Criteria:

  1. Clinically significant anemia associated with iron, vitamin B12, or folate deficiency; autoimmune or hereditary hemolytic anemia; gastrointestinal bleeding; or thalassemia.

  2. Active infection.

  3. A history of malignancy within the previous 5 years, except for cured basal cell carcinoma of the skin or cervical carcinoma in situ.

  4. Significant hepatic or renal dysfunction, or dysfunction of another major organ.

  5. Other serious conditions that, in the investigator's judgment, may affect participant safety or compliance, including:

    • Uncontrolled diabetes mellitus, with blood glucose above 250 mg/dL or 13.9 mmol/L.
    • Hypertension that cannot be controlled to a systolic blood pressure below 160 mmHg and a diastolic blood pressure below 100 mmHg despite combination antihypertensive treatment.
    • Peripheral neuropathy of grade 2 or higher according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0.
  6. Previous splenectomy.

  7. Previous treatment with any transforming growth factor-beta ligand inhibitor.

  8. Pregnancy or breastfeeding, women planning pregnancy during the study, or men with near-term plans to father a child.

  9. Suspected hypersensitivity to gecacitinib, luspatercept, or drugs of the same class.

  10. Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Gecacitinib + Luspatercept

gecacitinib 100 mg orally twice daily, combined with luspatercept at an initial dose of 1.0 mg/kg subcutaneously every 3 weeks

Gecacitinib will be administered orally at 100 mg twice daily in the fasting state. Dose adjustments will be based primarily on platelet counts and absolute neutrophil counts. Gecacitinib will be interrupted if the platelet count falls below 50 × 10^9/L and may be resumed when the platelet count recovers to at least 50 × 10^9/L.

Luspatercept will be administered by subcutaneous injection at an initial dose of 1.0 mg/kg every 3 weeks. The dose may be adjusted according to blood counts, up to a maximum of 1.75 mg/kg. Treatment may be interrupted if the predose hemoglobin level is at least 120 g/L or if hemoglobin increases rapidly by more than 20 g/L.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Percentage of Participants Achieving an Anemia Response
Tidsramme: 24 week

Anemia response is defined as conversion from red blood cell transfusion dependence at baseline to transfusion independence, or an increase in hemoglobin of at least 20 g/L in participants who do not require red blood cell transfusions and have a baseline hemoglobin level of 100 g/L or lower.

24 week

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Percentage of Participants With a Sustained Increase in Mean Hemoglobin of at Least 1.0 g/dL Without Transfusion
Tidsramme: 24 week

Percentage of participants achieving an increase in mean hemoglobin of at least 1.0 g/dL from baseline for at least 12 consecutive weeks without red blood cell transfusions.

24 week
Time to Anemia Response
Tidsramme: week 24

Time from the first dose of study treatment to the first documented anemia response.

week 24
Duration of Anemia Response
Tidsramme: week 24

The longest continuous duration of anemia response among participants who achieve an anemia response.

week 24
Change From Baseline in Red Blood Cell Transfusion Amount and Frequency
Tidsramme: week 24

Changes from baseline in the amount and frequency of red blood cell transfusions during study treatment.

week 24
Change From Baseline in Hemoglobin
Tidsramme: weeks 4, 8, 12, 16, 20, and 24

Change in hemoglobin concentration, measured in g/L, from baseline at scheduled treatment-period visits.

weeks 4, 8, 12, 16, 20, and 24
SVR35
Tidsramme: week 12 and 24

Percentage of participants achieving a reduction in spleen volume of at least 35% from baseline.

week 12 and 24
DoMSR
Tidsramme: week 24

Time from the first documented reduction in spleen volume of more than 35% from baseline to the first subsequent assessment showing a reduction of less than 35% from baseline.

week 24
MPN-SAF TSS
Tidsramme: weeks 4, 8, 12, 16, 20, and 24

Percentage of participants achieving a reduction of at least 50% from baseline in the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS).

weeks 4, 8, 12, 16, 20, and 24
Reduction in Fatigue Score
Tidsramme: week 24

Percentage of participants achieving a reduction of at least 50% from baseline in fatigue symptom score.

week 24
Adverse Events
Tidsramme: From the first dose through 28 days after the last dose.

Incidence and severity of adverse events, including events that develop or worsen during treatment and events occurring after treatment that are considered related to the study drugs by the investigator. Serious adverse events and adverse events leading to treatment interruption or discontinuation will also be recorded.

From the first dose through 28 days after the last dose.
PFS
Tidsramme: 12 month

Time from the first dose of study treatment to disease progression or death from any cause, whichever occurs first.

12 month
OS
Tidsramme: 12 month

Time from the first dose of study treatment to death from any cause.

12 month

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. november 2026

Primær fullføring (Antatt)

1. desember 2028

Studiet fullført (Antatt)

1. desember 2029

Datoer for studieregistrering

Først innsendt

9. november 2026

Først innsendt som oppfylte QC-kriteriene

9. november 2026

Først lagt ut (Faktiske)

16. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

16. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

9. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • K11529

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .